- Home
- STM vs BIIB Comparison
STM vs BIIB Comparison
Compare STM & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STM
- BIIB
- Stock Information
- Founded
- STM 1987
- BIIB 1978
- Country
- STM Switzerland
- BIIB United States
- Employees
- STM N/A
- BIIB N/A
- Industry
- STM Semiconductors
- BIIB Biotechnology: Pharmaceutical Preparations
- Sector
- STM Technology
- BIIB Health Care
- Exchange
- STM Nasdaq
- BIIB Nasdaq
- Market Cap
- STM 25.5B
- BIIB 28.6B
- IPO Year
- STM 1994
- BIIB 1991
- Fundamental
- Price
- STM $27.70
- BIIB $186.11
- Analyst Decision
- STM Buy
- BIIB Buy
- Analyst Count
- STM 7
- BIIB 23
- Target Price
- STM $39.80
- BIIB $273.59
- AVG Volume (30 Days)
- STM 4.0M
- BIIB 1.2M
- Earning Date
- STM 10-31-2024
- BIIB 10-30-2024
- Dividend Yield
- STM 1.30%
- BIIB N/A
- EPS Growth
- STM N/A
- BIIB N/A
- EPS
- STM 3.09
- BIIB 7.94
- Revenue
- STM $15,410,000,000.00
- BIIB $9,672,000,000.00
- Revenue This Year
- STM N/A
- BIIB N/A
- Revenue Next Year
- STM $10.35
- BIIB N/A
- P/E Ratio
- STM $8.86
- BIIB $23.41
- Revenue Growth
- STM N/A
- BIIB N/A
- 52 Week Low
- STM $26.63
- BIIB $181.31
- 52 Week High
- STM $51.27
- BIIB $268.30
- Technical
- Relative Strength Index (RSI)
- STM 42.91
- BIIB 36.36
- Support Level
- STM $27.15
- BIIB $187.70
- Resistance Level
- STM $28.07
- BIIB $191.19
- Average True Range (ATR)
- STM 0.54
- BIIB 3.60
- MACD
- STM 0.02
- BIIB 0.26
- Stochastic Oscillator
- STM 42.29
- BIIB 19.03
About STM STMicroelectronics N.V.
A merger between Italian firm SGS Microelettronica and the nonmilitary business of Thomson Semiconductors in France formed STMicroelectronics in 1987. STMicroelectronics is a leader in a variety of semiconductor products, including analog chips, discrete power semiconductors, microcontrollers, and sensors. It is an especially prominent chip supplier to the industrial and automotive industries.
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel multiple sclerosis drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is copromoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with Sobi) were spun off as part of Bioverativ in 2017. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (post-partum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology-related fields.